The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Open accessAbstract
BACKGROUND: Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. METHODS: In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life. RESULTS: Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. CONCLUSIONS: Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Wárlám-Rodenhuis, C. C., De Winter, K. A., Lutgens, L. C., van den Bergh, A. C., van de Steen-Banasik, E., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02139-5 · Cited by 1,773
Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., & Bell, J. G. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.048 · Cited by 1,671
Self-citationNout, R., Smit, V., Putter, H., Jürgenliemk-Schulz, I., Jobsen, J., Lutgens, L., van der Steen-Banasik, E., Mens, J., Slot, A., Kroese, M. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62163-2 · Cited by 1,150
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
Self-citationAalders, J. G., Abeler, V. M., Kolstad, P., et al. (1980) · PubMed · Cited by 795
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30079-2 · Cited by 641
Self-citationFleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565
Högberg, T., Signorelli, M., Oliveira, C., Fossati, R., Lissoni, A. A., Sorbe, B., Andersson, H., Grénman, S., Lundgren, C., Rosenberg, P., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.002 · Cited by 451
Susumu, N., Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S., & Kudo, R. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.09.029 · Cited by 445
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Cancer of the corpus uteri: 2021 update
Koskas, M., Amant, F., Mirza, M. R., & Creutzberg, C. L. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13866 · Cited by 298
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16318 · Cited by 163
Ladbury, C., Zarinshenas, R., Semwal, H., Tam, A., Vaidehi, N., Rodin, A. S., Liu, A., Glaser, S., Salgia, R., & Amini, A. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-1626 · Cited by 86
Chen, S., Wang, C., Meng, Y., Li, P., Pan, Y., He, M., & Ni, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s441418 · Cited by 7
Metadata
- Authors
- Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., Powell, M. A., O’Malley, D. M., Spirtos, N. M., Small, W., Tewari, K. S., Richards, W. E., Nakayama, J., Matulonis, U. A., Huang, H. Q., & Miller, D. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-13
- Volume
- 380
- Issue
- 24
- Pages
- 2317-2326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2949349304
- Cited by
- 477
- References
- 18
- FWCI
- 56.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. https://app.cochat.ai/papers/10.1056/nejmoa1813181
- The paper
- Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., Powell, M. A., O’Malley, D. M., Spirtos, N. M., Small, W., Tewari, K. S., Richards, W. E., Nakayama, J., Matulonis, U. A., Huang, H. Q., & Miller, D. S. (2019). Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1813181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.